Cortexin

Overview

Cortexin is a polypeptide nootropic that sits at the intersection of Eastern European pharmaceutical science and the broader peptide bioregulator framework developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology.

Like thymalin (thymus-derived), cortexin is an organ-specific extract — derived from the cerebral cortex of cattle or pigs, containing a standardized mixture of low-molecular-weight peptides. The "organ-specific bioregulator" concept holds that peptides derived from a target organ carry information that, when administered, preferentially acts on that same organ in the recipient.

Cortexin is manufactured by Geropharm and has been a registered drug in Russia since the 1980s, widely used in neurology departments for acute and chronic neurological conditions. Western pharmaceutical approval does not exist, leaving it in a regulatory gray area as a research compound outside Russia and Eastern Europe.

Mechanism

Multi-Component Neuropeptide Activity

Unlike single-peptide nootropics, cortexin's activity reflects the combined effects of its polypeptide mixture. Characterized components include:

1. ACTH-like fragments: Activate central dopaminergic and noradrenergic systems → improved attention and learning
2. Neuropeptide Y analogues: Anxiolytic effects, memory consolidation
3. Thyrotropin-releasing hormone (TRH) fragments: Stimulate acetylcholine release and cognitive processing
4. Delta sleep-inducing peptide (DSIP) content: Contributes to sleep quality normalization
5. Unknown oligopeptides: Multiple uncharacterized components with neuroprotective activity

BDNF and Neuroplasticity

The most consistently reported molecular effect of cortexin in research:

• Upregulates BDNF (brain-derived neurotrophic factor) expression in hippocampus and cortex
• BDNF supports synaptic plasticity, long-term potentiation, and neuronal survival
• Post-stroke BDNF elevation is associated with improved functional recovery

Anti-Excitotoxic Protection

Cortexin reduces glutamate excitotoxicity during ischemia:

• Decreases NMDA receptor overactivation
• Reduces intracellular calcium overload
• Activates antioxidant pathways (SOD, catalase upregulation)
• Reduces caspase-3 activation (anti-apoptotic)

Clinical Context: Stroke Rehabilitation

Russian and Eastern European stroke rehabilitation routinely incorporates cortexin as part of standard care. In the largest published trials:

• 10-day courses repeated 2–3 times over 6 months
• Primary endpoints: NIHSS neurological deficit scores, Rankin scale functional independence
• Consistent finding: faster and more complete neurological recovery vs. standard care alone
• Most benefit seen in ischemic (not hemorrhagic) stroke within 48–72h of onset

Comparison: Cortexin vs. Cerebrolysin

| Parameter | Cortexin | Cerebrolysin | |-----------|----------|--------------| | Source | Cattle/porcine cortex | Porcine brain (broader) | | Route | IM | IV | | Dose | 5–20mg | 5–60mL | | Evidence base | Russian trials | International trials + some RCTs | | Availability | Eastern Europe | Wider international availability |